OncoMatch/Clinical Trials/NCT07382817
Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
Is NCT07382817 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies JV-394 for neoplasms.
Treatment: JV-394 — The goal of this clinical research study is to find the highest tolerable dose of JV-394 (a type of autologous CAR-T cell therapy) that can be given to patients who have T/NK cell lymphoma that is relapsed or refractory. The safety and possible side effects of JV-394 will also be studied.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: KLRD1 overexpression (≥50% of tumor cells positive for CD94 by flow cytometry or IHC)
≥50% of tumor cells are positive for CD94 by flow cytometry or IHC. Historical documentation of CD94 expression in the tumor is acceptable if available. If there is no historical documentation of CD94 expression, testing of archival tumor tissue or fresh tumor biopsy is required.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Absolute neutrophil count of ≥1.0×10^9 /L; Absolute lymphocyte count of ≥0.1×10^9 /L; Platelet count of ≥75×10^9 /L
Kidney function
Creatinine clearance (as estimated by Cockcroft Gault) ≥45 mL/min
Liver function
Serum alanine transaminase (ALT) / aspartate transaminase (AST) ≤5 times the upper limit of normal (ULN); Total bilirubin ≤2 mg/dL, except in patients with Gilbert's syndrome
Cardiac function
Cardiac ejection fraction ≥45% with no evidence of clinically significant pericardial effusion
Absolute neutrophil count of ≥1.0×10^9 /L. Absolute lymphocyte count of ≥0.1×10^9 /L. Platelet count of ≥75×10^9 /L. Creatinine clearance (as estimated by Cockcroft Gault) ≥45 mL/min. Serum alanine transaminase (ALT) / aspartate transaminase (AST) ≤5 times the upper limit of normal (ULN). Total bilirubin ≤2 mg/dL, except in patients with Gilbert's syndrome. Cardiac ejection fraction ≥45% with no evidence of clinically significant pericardial effusion. Baseline oxygen saturation ≥92% on room air.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas M. D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify